

## Erratum

In the article “Quantification of Task-Specific Glucose Metabolism with Constant Infusion of  $^{18}\text{F}$ -FDG” by Hahn et al. (*J Nucl Med.* 2016;57:1933–1940), the absolute values of CMRGlu in Table 1 are lower than initially reported because of a cross-calibration error. Because this was a systematic scaling error, the statistics and interpretations remain unchanged. The authors regret the error.

**TABLE 1**  
Task-Specific Changes in Glucose Metabolism for Eyes-Open Condition and Right-Finger Tapping as Compared with Baseline

Region	x (mm)	y (mm)	z (mm)	t value	CMRGlu baseline ( $\mu\text{mol}/100\text{ g}/\text{min}$ )	CMRGlu task ( $\mu\text{mol}/100\text{ g}/\text{min}$ )	Signal change (%)
Eyes open > baseline							
Lingual L	-4	-88	-14	10.4*	25.6 ± 4.4	0.9 ± 0.4	3.6 ± 1.4
Intracalcarine L	-8	-84	8	10.0*	25.7 ± 4.2	0.8 ± 0.3	3.0 ± 1.1
Supracalcarine R	16	-66	14	10.4*	28.3 ± 4.6	0.6 ± 0.2	2.2 ± 0.8
Occipital pole R	8	-96	-8	9.8*	23.7 ± 5.3	0.9 ± 0.4	4.0 ± 1.9
Cuneus	0	-82	26	11.8*	27.6 ± 4.2	0.6 ± 0.2	2.3 ± 0.8
Cerebellum crus II L	-12	-88	-24	17.2*	20.8 ± 3.4	1.3 ± 0.4	6.1 ± 1.7
Cerebellum crus II R	8	-80	-28	9.4*	21.9 ± 3.5	1.2 ± 0.6	5.5 ± 2.2
Cerebellum VI L	-28	-54	-28	16.5*	22.5 ± 3.2	0.7 ± 0.2	3.1 ± 0.8
Cerebellum crus I L	-26	-88	-30	11.9*	15.7 ± 2.9	0.6 ± 0.3	4.0 ± 1.5
Cerebellum crus I R	52	-52	-34	12.9*	15.4 ± 2.9	0.9 ± 0.3	5.8 ± 1.8
Cerebellum vermis IX L	-2	-54	-30	11.8*	17.1 ± 2.4	0.7 ± 0.3	4.2 ± 1.5
Hippocampus L	-30	-18	-12	9.7*	16.3 ± 2.4	0.8 ± 0.3	5.2 ± 2.2
Eyes open < baseline							
Frontal superior L	-18	32	46	-9.2*	27.9 ± 5.3	-0.6 ± 0.3	-1.9 ± 0.8
Central L	-40	-24	58	-0.7	27.6 ± 4.3	-0.1 ± 0.6	-0.4 ± 2.2
Finger tapping > baseline							
Central L	-40	-24	58	11.5*	27.6 ± 4.3	1.8 ± 0.8	6.3 ± 2.8
Precentral L	-32	-16	70	10.7*	19.0 ± 3.5	1.1 ± 0.6	5.7 ± 2.5
Hippocampus L	-28	-16	-12	12.1*	16.3 ± 2.5	0.9 ± 0.4	5.6 ± 1.9
Cerebellum VI L	-32	-56	-26	13.0*	24.8 ± 3.5	1.1 ± 0.3	4.3 ± 1.3
Cerebellum VI R	8	-64	-10	11.3*	21.8 ± 2.9	0.8 ± 0.4	3.5 ± 1.3
Cerebellum crus I R	52	-52	-32	9.4*	16.6 ± 3.3	0.8 ± 0.4	5.0 ± 2.2
Finger tapping < baseline							
Intracalcarine L	-8	-84	8	-0.8	25.7 ± 4.2	-0.1 ± 0.6	-0.3 ± 2.3

\* $P < 0.05$ , FWE-corrected voxel level.

Significance thresholds were  $t = 8.7$  for  $P < 0.05$ , FWE-corrected, and  $t = 3.8$  for  $P < 0.001$ , uncorrected. Coordinates and  $t$  values were obtained from SPM analysis. Corresponding CMRGlu as obtained from Patlak plot is shown for baseline condition and each task as well as percentage signal changes from baseline.

## Erratum

There is an error in the financial disclosure of “Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions” by Deroose et al. (*J Nucl Med.* 2016;57:1949–1956). The correct disclosure is as follows: “Dr. Deroose is a consultant/advisor for Sirtex and Ipsen, is a meeting participant/lecturer for Bayer, and is involved in a scientific study/trial for Advanced Accelerator Applications (AAA). AAA ( $^{68}\text{Ga}$ -DOTATATE,  $^{177}\text{Lu}$ -DOTATATE,  $^{18}\text{F}$ -DOPA, and  $^{18}\text{F}$ -FDG), Sirtex (selective internal radiotherapy spheres), and Ipsen (lanreotide and radiolabeled SSTR antagonists) produce diagnostic and therapeutic agents described in this article.” The authors regret the error.